Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling

Clearside Biomedical, Inc.

2023-Q1 EPS reported -$0.13 revenue$347,000

Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.
Cash and equivalents $34.4M; company expects sufficient for at least next 12 months.
XIPERE (suprachoroidal triamcinolone) commercially launched in U.S. by Bausch + Lomb for uveitic macular edema.
CLS-AX Phase 1/2a OASIS trial: Cohort 4 enrolling at 1.0 mg; no dose-limiting toxicities in Cohort 3; safety data expected Q4 2022.
Benjamin R. Yerxa appointed to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.